Innate Pharma Advances Lacutamab into Phase 3 Trial with Sobi

Innate Pharma announces the advancement of lacutamab to Phase 3 of the TELLOMAK-3 study following a strategic partnership with Sobi. This study, focused on Sézary syndrome, aims for an accelerated marketing authorization application, based on promising Phase 2 data.

An initial financial contribution of $75 million, combined with the partnership with Sobi, will fund this progression, extending Innate's financial horizon to the third quarter of 2027. This fund will support the application for lacutamab to health authorities.

Furthermore, Markus Jensen has been appointed Chief Medical Officer of Innate, succeeding Sonia Quaratino. With his extensive experience at Bayer and in clinical pharmacology, Jensen will ensure the continuity of key projects, including TELLOMAK-3 and IPH4502.